Multiple Myeloma Clinical Trial
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd); Part 3 includes participants with t(11;14) positive R/R multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd).
Part 1 and Part 2 are non-randomized and will be initiated with a dose-escalation phase in which increasing doses of venetoclax will be given with fixed doses of daratumumab and dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone (Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion phase. Part 3 will include a randomized, open-label expansion phase with participants receiving venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd).
Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
Participant has relapsed or refractory multiple myeloma with documented evidence of progression that occurred during or after the participant's last treatment regimen based on investigator's determination of International Myeloma Working Group (IMWG) criteria.
Measurable disease confirmed by central lab at Screening, defined by at least 1 of the following: Serum M-protein >= 1.0 g/dL (>= 10 g/L), OR Urine M-protein >= 200 mg/24 hours, OR Serum free light chain (FLC) >= 10 mg/dL, provided serum FLC ratio is abnormal in participants who do not have measurable disease by Serum Protein Electrophoresis (SPEP) or Urine Protein Electrophoresis (UPEP) criteria.
Participant has received previous multiple myeloma treatment as defined in the protocol.
Bone marrow aspirate samples have been collected.
To qualify for Part 1 and 3, the participant must be t(11;14) positive as determined by an analytically validated Fluorescent In Situ Hybridization (FISH) assay per central laboratory testing.
Participants must have adequate hematologic, renal and hepatic function.
Previous treatment with venetoclax or other B-Cell Lymphoma 2 (BCL-2) inhibitor
For participants in Parts 1 and 2: Previous treatment with daratumumab or other anti-CD38 therapy. For participants in Part 3: Prior daratumumab or other anti-CD38 antibody therapy exposure that meets ANY of the following criteria:
Failure to achieve at least a PR to most recent therapy with daratumumab or other anti-CD38 therapy.
Daratumumab or other anti-CD38 antibody therapy was discontinued due to toxicity.
Relapse within 60 days of intensive treatment (at least every other week) of daratumumab or other anti-CD38 antibody therapy.
Prior treatment with daratumumab or other anti-CD38 antibody within 6 months prior to first dose of study drug.
For participants in Part 2 and 3:
Participant is refractory to any proteasome inhibitor, defined as progression on or within 60 days of the last dose of a proteasome inhibitor-containing regimen.
Participant has had prior treatment with proteasome inhibitor within 60 days prior to first dose of study drug.
Treatment with anti-myeloma chemotherapy, radiotherapy, biological, immunotherapy or an investigational therapy, including targeted small molecule agents within 2 weeks or 5 half-lives (whichever is longer and/or applicable) before first dose.
Treatment with anti-myeloma monoclonal antibodies within 6 weeks prior to first dose.
Recent corticosteroid therapy at a cumulative dose equivalent to >= 140 mg of prednisone, cumulative dose equivalent to >= 40 mg of dexamethasone, or a single dose equivalent to >= 40 mg of dexamethasone within 2 weeks prior the first dose of study drug.
Known central nervous system involvement of multiple myeloma.
Significant history of medical conditions as listed in the protocol.
History of other active malignancies including myelodysplatic syndromes (MDS) within the past 3 years with the exceptions of:
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin.
Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment
Previous malignancy with no evidence of disease confirmed and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study.
Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Has a hypersensitivity or allergy to any of the components of study therapy, excipient or boron.
Known allergies, hypersensitivities, or intolerance to monoclonal antibodies or human proteins, or their excipients, or known sensitivity to mammalian-derived products (see daratumumab prescribing information).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 38 Locations for this study
Aurora Colorado, 80045, United States
Tampa Florida, 33612, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60637, United States
Boston Massachusetts, 02215, United States
Boston Massachusetts, 02215, United States
Hackensack New Jersey, 07601, United States
Buffalo New York, 14263, United States
New York New York, 10021, United States
Charlotte North Carolina, 28203, United States
Durham North Carolina, 27710, United States
Winston-Salem North Carolina, 27157, United States
Portland Oregon, 97239, United States
Seattle Washington, 98109, United States
Darlinghurst New South Wales, 2010, Australia
Kogarah New South Wales, 2217, Australia
Adelaide South Australia, 5000, Australia
Box Hill Victoria, 3128, Australia
Fitzroy Melbourne Victoria, 3065, Australia
Melbourne Victoria, 3000, Australia
Perth Western Australia, 6000, Australia
Calgary Alberta, T2N 4, Canada
Edmonton Alberta, T6G 1, Canada
Montreal Quebec, H4A 3, Canada
Copenhagen Ø Hovedstaden, 2100, Denmark
Aarhus N Midtjylland, 8200, Denmark
Odense C Syddanmark, 5000, Denmark
Vejle Syddanmark, 7100, Denmark
Limoges CEDEX 1 Franche-Comte, 87042, France
Tours CEDEX 9 Indre-et-Loire, 37044, France
Nantes Pays-de-la-Loire, 44000, France
Poitiers Poitou-Charentes, 86000, France
Villejuif Cedex Val-de-Marne, 94805, France
Paris , 75010, France
Freiburg Baden-Wuerttemberg, 79106, Germany
Cologne , 50937, Germany
Nagoya shi Aichi, 467-8, Japan
Kamogawa-shi Chiba, 296-8, Japan
Matsuyama-shi Ehime, 790-8, Japan
Gifu-shi Gifu, 500-8, Japan
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.